Free Trial
OTCMKTS:INBP

Integrated BioPharma (INBP) Stock Price, News & Analysis

Integrated BioPharma logo
$0.29 +0.00 (+0.81%)
As of 07/23/2025 03:38 PM Eastern

About Integrated BioPharma Stock (OTCMKTS:INBP)

Key Stats

Today's Range
$0.28
$0.29
50-Day Range
$0.26
$0.36
52-Week Range
$0.16
$0.42
Volume
11,600 shs
Average Volume
5,372 shs
Market Capitalization
$8.84 million
P/E Ratio
7.13
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive INBP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Integrated BioPharma and its competitors with MarketBeat's FREE daily newsletter.

INBP Stock News Headlines

INBP Integrated BioPharma, Inc.
I was wrong about Trump
I made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his advisors, I believed him. I believed the promise that he would finally confront the single most dangerous threat to American life. That he would fix the ticking time bomb I’ve been warning about for 15 years. But I was wrong.
Integrated Biopharma Inc (INBP)
Integrated BioPharma, Inc. (INBP)
See More Headlines

INBP Stock Analysis - Frequently Asked Questions

Integrated BioPharma's stock was trading at $0.3297 at the beginning of 2025. Since then, INBP shares have decreased by 13.5% and is now trading at $0.2853.

Integrated BioPharma Inc. (OTCMKTS:INBP) announced its earnings results on Wednesday, May, 14th. The company reported $0.02 earnings per share (EPS) for the quarter. The business earned $13.95 million during the quarter. Integrated BioPharma had a trailing twelve-month return on equity of 6.36% and a net margin of 2.37%.

Shares of INBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Integrated BioPharma investors own include GSK (GSK), Invitae (NVTA), Exxon Mobil (XOM), Autodesk (ADSK), Adaptive Biotechnologies (ADPT), Analog Devices (ADI) and Adaptimmune Therapeutics (ADAP).

Company Calendar

Last Earnings
5/14/2025
Today
7/25/2025
Next Earnings (Estimated)
9/18/2025
Fiscal Year End
6/30/2026

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
OTCMKTS:INBP
CIK
1016504
Employees
150
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
$0.04
Trailing P/E Ratio
7.13
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$110 thousand
Net Margins
2.37%
Pretax Margin
3.55%
Return on Equity
6.36%
Return on Assets
4.84%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
3.72
Quick Ratio
1.70

Sales & Book Value

Annual Sales
$50.32 million
Price / Sales
0.18
Cash Flow
$0.04 per share
Price / Cash Flow
6.44
Book Value
$0.64 per share
Price / Book
0.45

Miscellaneous

Outstanding Shares
30,980,000
Free Float
10,160,000
Market Cap
$8.84 million
Optionable
Not Optionable
Beta
0.81

Social Links

Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (OTCMKTS:INBP) was last updated on 7/25/2025 by MarketBeat.com Staff
From Our Partners